AlyAHA
  • 0 replies
  • 123 views
  • 0 followings
AlyAHA, June 16,  2020  6:12pm EST

Hypertrophic cardiomyopathy (HCM) patient opportunity

Hypertrophic cardiomyopathy (HCM) patients can register and participate in a virtual drug development meeting. Comments and questions they will be able to ask throughout the meeting will be used by the FDA to hear what HCM patients go through.

Patient Focused Drug Development Meeting

Friday, June 26th from 9:45 AM EDT to 2:30 PM EDT

Registration: https://www.4hcm.org/ev_calendar_day.asp?date=6%2F26%2F20&eventid=140

The HCMA will be holding a fully virtual PFDD Patient-Focused Drug Development Meeting

•Time: log-on 9:45am eastern time

•Meeting starts: 10:00am eastern time

•Opening session: 10:00-10:30am

•Lisa Salberg CEO HCMA

•Martin Maron, MD Director of the HCM Institute, Tufts Medical Center, Boston and Chanin T. Mast HCM Center , Morristown, NJ

•James Valentine

• Preston Dummon MD, FACP, FACC Medical Officer Division of Cardiovascular and Renal Products

•Panel 1 Burden of Disease: 10:30-11:00am

•Hear from our panelists

•Public input on Panel 1: 11:00am to Noon

•Interactive session including audience polling, call in comments and video comments from live audience

•Break – 30 minute

•Session 2 opening comments from FDA

•Panel 2 Therapies and Hopes for the Future: 12:30- 1:00pm

•Hear from our panelists

•Public input on Panel 2: 1:00-2:00pm

•Interactive session including audience polling, call in comments and video comments from live audience

•Closing comments: 2:00-2:20pm


Please put down "AHA-Patient", "AHA-Caregiver" or "AHA-Family Member" for your Organization Name, if you do not have an organization.

Email SupportNetwork@heart.org if you have any questions!

dark overlay when lightbox active
dark overlay when lightbox active
dark overlay when lightbox active
dark overlay when lightbox active